P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM)
Robert F. Cornell,Hari Parameswaran,Shijie Tang,Alyssa Barnstead,Noa Biran,Natalie S. Callander,Ajai Chari,Saurabh Chhabra,Mark A. Fiala,Zhubin Gahvari,Ujjawal H. Gandhi,Kelly N. Godby,Ridhi Gupta,Sundar Jagannath,Megan Jagosky,Yubin Kang,Ankit Kansagra,Michael Kauffman,Saranya Kodali,Shaji Kumar,Arjun Lakshman,Michaela Liedtke,Sagar Lonial,Xiwen Ma,Ehsan Malek,Joshua Mansour,Elizabeth McGehee,Swapna Narayana,Amarendra K. Neppalli,Barry Paul,Paul G. Richardson,Emma C. Scott,Sharon Shacham,Jatin P. Shah,David S. Siegel,Elvira Umyarova,Saad Z. Usmani,William Varnado,Ravi Vij,Luciano J. Costa +39 more
Journal ArticleDOI
Atypical Presentation of Miliary Tuberculosis With Hepatic Involvement Early After Renal Transplantation
Journal ArticleDOI
Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Paul G. Richardson,Ajay K. Nooka,Hang Quach,Suzanne Trudel,David Routledge,David Routledge,Kevin W. Song,Hareth Nahi,Sofia Paul,Josephine Khan,Maria Brouch,Geraldine Ferron-Brady,Anne Yeakey,Chris Shelton,Rocio Montes de Oca,L. Mary Smith,Ellie Im,Christoph M. Ahlers,Elaine M. Paul,Beata Holkova,Ira Gupta,Brandon E. Kremer,Paula Rodriguez-Otero +22 more
TL;DR: The primary objectives of the DREAMM-5 study are to identify the RP2D (DE phase) and the overall response rate (≥partial response, CE phase), along with safety and tolerability, for each combination treatment.
Journal ArticleDOI
A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety
Omar Nadeem,Robert A. Redd,Laura Stampleman,Jeffrey Matous,Andrew Yee,Jeffrey A. Zonder,Andrew Kin,Jacalyn Rosenblatt,Mark Bustoros,Julia Prescott,Alexandra Savell,Kathleen Guimond,Erin Frey,Rachel Styles,Adrienne Bielawski,Cody J. Boehner,Nang Kham Su,Adam S. Sperling,Giada Bianchi,Jacob P. Laubach,Jorge J. Castillo,Nikhil C. Munshi,Kenneth C. Anderson,Paul G. Richardson,Lorenzo Trippa,Irene M. Ghobrial +25 more
TL;DR: DARA is very well tolerated among patients with newly diagnosed and relapsed multiple myeloma and none have discontinued therapy due to toxicity, and median overall survival and progression-free survival have not been reached.
Journal ArticleDOI
Toward a new therapeutic backbone in myeloma
TL;DR: The combination of bortezomib and thalidomide with the more traditional doublet of melphalan and prednisone has delivered success in patients with multiple myeloma.